Role of serum interleukin-6 in deciding therapy for multidrug resistant oral lichen planus | Zendy

Sinny Goel | Zendy; A Marwah | Zendy; Sandeep Kaushik | Zendy; VK Garg | Zendy; Santosh Kumar Gupta | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Role of serum interleukin-6 in deciding therapy for multidrug resistant oral lichen planus

Author(s) -

Sinny Goel,

A Marwah,

Sandeep Kaushik,

VK Garg,

Santosh Kumar Gupta

Publication year - 2015

Publication title -

journal of clinical and experimental dentistry

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.481

H-Index - 23

ISSN - 1989-5488

DOI - 10.4317/jced.52376

Subject(s) - oral lichen planus , methotrexate , medicine , multiple drug resistance , pimecrolimus , interleukin , gastroenterology , immunology , calcineurin , drug resistance , cytokine , transplantation , biology , microbiology and biotechnology

Oral lichen planus (OLP) is a T cell mediated immune response. T cells locally present in the involved tissues release cytokines like interleukin-6 (IL-6), which contributes to pathogenesis of OLP. Also IL-6 has been associated with multidrug resistance protein (MRP) expression by keratinocytes. Correspondingly, upregulation of MRP was found in OLP. We conducted this study to evaluate the effects of various drugs on serum IL-6 in OLP; and correlation of these effects with the nature of clinical response and resistance pattern seen in OLP lesions with various therapeutic modalities. Thus we evaluated the role of serum IL-6 in deciding therapy for multidrug resistant OLP.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research